Abstract:Sllll'RiillaryErythema multfforme (EM) represents a syndrome of chronic recurrent inflammatory skin disease. Depending on the severity and extent of skin and mucosal involvement, it is defined either as EM minor or EM major. In this study we demonstrate the presence of autoantibodies (aAbs) against desmoplakin I and II, two major proteins of the desmosomal plaque, in six of six patients with the severe variant of EM, EM major. Light microscopic studies of lesional skin and mucous membranes localized in vivo bo… Show more
“…A small number of patients with recurrent erythema multiforme major have antibodies against desmoplakins and will therefore have a positive indirect IF on bladder epithelium. These cases are distinguished from PNP in several ways: (1) they do not have an underlying malignancy; (2) they do not have antibodies against the plakin proteins that are more speci¢c for PNP, that is, envoplakin and periplakin; and (3) the antibodies are transient and are only detecable during episodes of active disease (Foedinger et al, 1995). The autoantibodies in PNP are constantly present.…”
“…A small number of patients with recurrent erythema multiforme major have antibodies against desmoplakins and will therefore have a positive indirect IF on bladder epithelium. These cases are distinguished from PNP in several ways: (1) they do not have an underlying malignancy; (2) they do not have antibodies against the plakin proteins that are more speci¢c for PNP, that is, envoplakin and periplakin; and (3) the antibodies are transient and are only detecable during episodes of active disease (Foedinger et al, 1995). The autoantibodies in PNP are constantly present.…”
“…One reason for the different outcome of our study compared with the initial work (Foedinger et al, 1995(Foedinger et al, , 1996 might be the tight window between diagnosis of the disease and serum sampling in our cohort. This may have reduced the detection of epiphenoma following the preceding tissue destruction due to an extended inflammatory response (Cozzani et al, 2011).…”
mentioning
confidence: 79%
“…Infiltrating TO THE EDITOR Erythema exsudativum multiforme majus (EEMM) is a rare condition affecting both skin and mucous membranes. It is assumed that humoral immune reponses may contribute to the pathogenesis of the disease, and the presence of autoantibodies was described in 7 of 10 EEMM patients (Foedinger et al, 1995(Foedinger et al, , 1996. These autoantibodies were associated with desmosomal staining by direct immunofluorescence microscopy of skin and by indirect immunofluorescence tests using monkey esophagus as a substrate, and they produced 210/ 250 kDa bands by immunoblotting of epidermal extracts, and immunoprecipitated proteins of apparently 210/250 kDa from lysates of human keratinocytes.…”
“…In fact, several reports demonstrate penetration of IgG autoantibody into living cells (19,20). Notably in keratinocytes, by using passive transfer and in vitro cell culture systems, a series of recent investigations have also demonstrated that IgG autoantibodies to desmoplakin I/II, entirely intracellular desmosomal antigens, can get into living cells and reach the target antigens (21)(22)(23). Moreover, anti-nuclear IgG antibodies from patients with systemic lupus erythematosus have been shown to penetrate into living epithelial cells via receptor-mediated endocytosis and subsequently localize to the corresponding intracellular target antigens (24).…”
Lichen sclerosus is a common, acquired chronic inflammatory skin disease of unknown etiology, although circulating autoantibodies to the glycoprotein extracellular matrix protein 1 (ECM1) have been detected in most patients' sera. We have examined the nature of ECM1 epitopes in lichen sclerosus sera, developed an ELISA system for serologic diagnosis, and assessed clinicopathological correlation between ELISA titer and disease. Epitope-mapping studies revealed that lichen sclerosus sera most frequently recognized the distal second tandem repeat domain and carboxyl-terminus of ECM1. We analyzed serum autoantibody reactivity against this immunodominant epitope in 413 individuals (95 subjects with lichen sclerosus, 161 normal control subjects, and 157 subjects with other autoimmune basement membrane or sclerosing diseases). The ELISA assay was highly sensitive; 76 of 95 lichen sclerosus patients (80.0%) exhibited IgG reactivity. It was also highly specific (93.7%) in discriminating between lichen sclerosus and other disease/control sera. Higher anti-ECM1 titers also correlated with more longstanding and refractory disease and cases complicated by squamous cell carcinoma. Furthermore, passive transfer of affinity-purified patient IgG reproduced some histologic and immunopathologic features of lichen sclerosus skin. This new ELISA is valuable for the accurate detection and quantification of anti-ECM1 autoantibodies. Moreover, the values may have clinical significance in patients with lichen sclerosus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.